Résumé
The Oncology Translational Research (OTR) Department at Novartis Biomedical Research is a global, laboratory-based research group, supporting the development of novel therapeutics in the Novartis Biomedical Research Oncology Disease Area.
Within OTR, the Oncology Pathology and Biomarkers (OPB) team leverages tissue-, cell-, and soluble protein–based assays to profile target epidemiology and biology, elucidate drug mechanisms of action, and define response/resistance biomarkers, from early target discovery through Phase 3 clinical development. OPB is seeking a motivated, inquisitive scientist to design and execute imaging-driven experiments that inform clinical biomarker strategies and accelerate Novartis Oncology drug candidates.
About the Role
The successful candidate will generate rigorous, high-quality data to propel translational research programs. By applying automated immunohistochemistry, immunofluorescence, and quantitative image analysis, they will help identify molecular predictors of response to cancer therapies, mechanisms of resistance or persistence under treatment, and opportunities for combination strategies.
Working closely with the lab head and team members, the candidate will flexibly contribute to both local and global projects and proactively share expertise across groups spanning the full Oncology portfolio, including radioligand therapeutics (RLT).
Key responsibilities:
- Deliver high‐quality data to impact drug discovery and projects in clinical development
- Design and conduct experiments and procedures requiring scientific and technical knowledge of immunohistochemistry and immunofluorescence
- Devise new techniques around tissue-based biomarkers to advance drug development and early discovery programs
- Supervise the development of multiplex IHC, FIHC and ISH assays
- Conduct in-depth image analysis of whole slide images using established platforms
- Consolidate, report data and present in context as needed
- Efficiently manage and maintain a functional laboratory, technical equipment and reagents
- Stay updated on the latest developments and trends in the field of Oncology and Radioligand Therapy
Role Requirements:
- MSc or BSc or qualified Lab Technician in Biological Sciences or other relevant discipline with minimum 2 years of histology laboratory experience
- Advanced/Fluent English oral and written
- Must have experience developing singleplex and multiplex immunohistochemistry and immunofluorescence tissue-based assays
- Proven experience with advanced image analysis using various software tools, including HALO
- Experience working with cross-functional teams and demonstrated ability to independently drive projects in a matrixed environment
- Knowledge of cancer signaling/biology is preferred, background in radioligand development and autoradiography is a plus
· Excellent organizational and communication skills
Languages :
- English.
Novartis is committed to working with and providing reasonable accommodation to all individuals. If, because of a medical condition or disability, you need a reasonable accommodation for any part of the recruitment process, or in order to receive more detailed information about the essential functions of a position, please send an e-mail to inclusion.switzerland@novartis.com and let us know the nature of your request and your contact information. Please include the job requisition number in your message
Why Novartis: Helping people with disease and their families takes more than innovative science. It takes a community of smart, passionate people like you. Collaborating, supporting and inspiring each other. Combining to achieve breakthroughs that change patients’ lives. Ready to create a brighter future together? https://www.novartis.com/about/strategy/people-and-culture
Benefits and Rewards: Read our handbook to learn about all the ways we’ll help you thrive personally and professionally: https://www.novartis.com/careers/benefits-rewards
Novartis is committed to building an outstanding, inclusive work environment and diverse teams' representative of the patients and communities we serve.
